$Arcturus Therapeutics Ltd.(ARCT)$Arcturus believes cellular responses induced by its ** vaccine candidate will compensate for the underwhelming neutralizing antibody levels in its interim Phase I/II data.
Eng Eong Ooi, a member of Arcturus’ vaccine platform SAB, hypothesized the robust T cell responses were behind the low antibody production following the second 5 µg ARCT-021 administration.
Ooi said their data showed that antibodies were not necessary for protection against SARS-CoV-2.
精彩评论